Adar1 Capital Management, LLC Inozyme Pharma, Inc. Put Options Transaction History
Adar1 Capital Management, LLC
- $500 Billion
- Q4 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding INZY
# of Institutions
101Shares Held
49.9MCall Options Held
3.7KPut Options Held
5.8K-
Adage Capital Partners Gp, L.L.C. Boston, MA5.16MShares$7.07 Million0.03% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$6.16 Million11.45% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$5.86 Million0.97% of portfolio
-
Affinity Asset Advisors, LLC New York, NY3.97MShares$5.44 Million1.97% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3.86MShares$5.29 Million0.43% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $55M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...